Outsourcing in Clinical Trials New England 20147-8 October 2014, Boston, MA
Welcome to the flagship event in our global Outsourcing in Clinical Trials Series. Last year over 400 pharmaceutical, biotechnology and medical device professionals attended Outsourcing in Clinical Trials New England event to learn from case-study based presentations, network with their peers, discover new solutions and services and find answers to all of their clinical challenges.
With such enthusiasm around this conference, this October’s event will once again bring together the industry leaders from within this hub for two days of presentations, case studies, panel discussions and roundtables, alongside the networking opportunity. With over 50 speakers participating, the content will cover all aspects of clinical outsourcing from informed sourcing and efficient contract negotiation through to effective management, monitoring and communication techniques.
We are pleased to announce an additional Speaker has joined the program. Rachel Morgan (Global Head, Clinical Science and Innovation, Translational Medicine, Novartis Institute Biomedical Research) will be joining David Connelly, (Chief Executive Officer, Cmed Group) for a presentation at 4pm on the first day of the event
Whether you are a senior professional in a global pharmaceutical company or a smaller company looking to expand, access to insight and knowledge about the latest pharmaceutical trends is vital.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news. The list of websites will be updated as soon as new events are live so check back regularly
We are always happy to see photos taken at our events! If you have any you would like to submit, please email firstname.lastname@example.org The Arena Team
Primary delegates for this event are those with responsibility for clinical outsourcing decisions and strategy within biotechnology, pharmaceutical, virtual and medical device companies throughout Southern California.
Outsourcing in Clinical Trials New England boasts a fantastic exhibition of clinical service providers and industry specialists. Our exhibition area is already filling up due to the fantastic launch event which took place this year. If you have a service or solution you would like to promote at this event, please use the details below to make contact with our commercial team.
Irish drug development firm Opsona Therapeutics has started a Phase I/II clinical trial of its lead drug candidate, OPN-305, in second-line lower (Low and intermediate-1) risk myelodysplastic syndrome (MDS) patients.
Medivation and Astellas Pharma have reported positive topline results from the Phase II TERRAIN trial comparing enzalutamide with bicalutamide in men with metastatic castration-resistant prostate cancer.
UK-based companies ImmuPharma and Simbec-Orion Group have entered into a collaboration agreement to execute ImmuPharma’s pivotal Phase III clinical trial of its lead compound Lupuzor to treat Lupus, a chronic, potentially life-threatening autoimmune …
US-based biotechnology firm Kineta has completed patient enrolment in its Phase Ib proof-of-concept clinical trial of its new, immune-sparing therapeutic, ShK-186, to treat psoriasis.
Dutch biopharmaceutical firm AM‐Pharma has started its Phase II trial of recAP (recombinant human Alkaline Phosphatase) to treat sepsis-associated acute kidney injury (AKI).
Belgium-based biotechnology firm Bone Therapeutics has reported positive efficacy results from the first cohort of four patients enrolled in the Phase I/IIa delayed-union trial with its allogeneic bone-forming cell product ALLOB.